Filgrastim biosimilar - Hospira

Drug Profile

Filgrastim biosimilar - Hospira

Alternative Names: Nivestim

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Hospira
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Febrile neutropenia
  • Phase I Neutropenia

Most Recent Events

  • 01 Jan 2017 Pfizer completes a phase I trial in Healthy volunteers in USA (SC) (NCT02923791)
  • 01 Oct 2016 Pfizer initiates enrolment in a phase I trial in Healthy volunteers in USA (SC) (NCT02923791)
  • 30 Sep 2016 Pfizer plans a phase I trial in Healthy volunteers in USA (SC) (NCT02923791)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top